Notably, AKT1, INS, and IL-6 emerged as central nodes, which were functionally associated with lipid metabolic and inflammation processes, particularly glycerophospholipid metabolism, suggesting their potential as key therapeutic targets of XYC for epilepsy treatment. Here, IL6 is linked to epilepsy.